Table 2. Univariate and multivariate analyses of overall survival in patients with HCC.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |||
| T stage (T2 & T3 & T4 vs. T1) | 370 | 2.126 (1.481–3.052) | <0.001* | 1.257 (0.763–2.071) | 0.369 | |
| Pathologic stage (stage III & stage IV vs. stage I & stage II) | 349 | 2.504 (1.727–3.631) | <0.001* | 1.787 (1.094–2.919) | 0.020* | |
| Tumor status (with tumor vs. tumor free) | 354 | 2.317 (1.590–3.376) | <0.001* | 1.743 (1.162–2.615) | 0.007* | |
| Residual tumor (R1 & R2 vs. R0) | 344 | 1.604 (0.812–3.169) | 0.174 | |||
| Histologic grade (G4 & G2 & G3 vs. G1) | 368 | 1.188 (0.721–1.958) | 0.499 | |||
| AFP (ng/mL) (>400 vs. ≤400) | 279 | 1.075 (0.658–1.759) | 0.772 | |||
| Vascular invasion (yes vs. no) | 317 | 1.344 (0.887–2.035) | 0.163 | |||
| EIF2S2 (high vs. low) | 373 | 2.031 (1.423–2.897) | <0.001* | 1.962 (1.320–2.915) | <0.001* | |
*, indicates statistically significant, P<0.05. EIF2S2, eukaryotic translation initiation factor 2 subunit beta; HCC, hepatocellular carcinoma; AFP, α-fetoprotein.